Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksLaunch of Copaxone 20 mg can add Rs 8-10 to FY19 EPS for Natco: HDFC Securities

    Launch of Copaxone 20 mg can add Rs 8-10 to FY19 EPS for Natco: HDFC Securities

    Natco Pharma rallies in trade as Mylan gets US Food and Drug Administration (US FDA) nod for Copaxone. In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities spoke about the impact and his strategy on the stock.

    October 04, 2017 / 14:42 IST

    Natco Pharma rallies in trade as Mylan gets US Food and Drug Administration (US FDA) nod for Copaxone.

    In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities spoke about the impact and his strategy on the stock.

    Chalke said launch of Copaxone 20 mg can add Rs 8-10 to FY19 earnings per share (EPS) for Natco.

    He further said that the company might wait for litigation to get over before launching Copaxone.

    Talking about Sun Pharmaceutical Industries, he said the Halol inspection is expected in this quarter.

    Watch accompanying video for more details.
    first published: Oct 4, 2017 02:42 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347